DRG Epidemiology’s coverage of RP comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the diagnosed prevalence of RP for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan in this report.

DRG Epidemiology’s RP forecast will answer the following questions:

  • Of all people diagnosed with RP, how many in each countryacross the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of RP over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following RP patient populations:

  • Diagnosed Prevalent Cases of Inherited Retinal Dystrophy
  • Diagnosed Prevalent Cases of RetinitisPigmentosa
  • Drug-Treated Prevalent Cases of RetinitisPigmentosa
  • Clinical Subtypes of RetinitisPigmentosa
  • Diagnosed Prevalent Cases of Usher Syndrome
  • Diagnosed Prevalent Cases of Bardet-Biedl Syndrome
  • Diagnosed Prevalent Cases with RPE65Mutation
  • Diagnosed Prevalent Cases of Leber'sCongenital Amaurosis
  • Diagnosed Prevalent Cases of Choroideremia

Note: coverage may vary by country and region.

Table of contents

  • Retinitis Pigmentosa - Epidemiology - Mature Markets Data

Author(s): Fjoralba Kristo, MD, MPH

Fjoralba Kristo has expertise in forecasting infectious diseases and chronic diseases in both the mature and global markets. She has extensive academic experience with quantitative and qualitative research methods.

Prior to joining Decision Resources Group, she completed a postdoctoral fellowship at University of Kentucky, Division of Cardiovascular Medicine, and more recently worked as Research Scientist at Massachusetts General Hospital, where she investigated mechanisms of inflammation in cardiovascular diseases. Fjoralba holds an MPH degree from Boston University School of Public Health, concentrating in Epidemiology and Biostatistics, and a medical degree from University of Medicine, Bucharest, Romania.